Key facts
- This page summarizes Wendy Pizarro Campbell's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Jun 2024, 20:56.
Wendy Pizarro Campbell - 17 Jun 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- Chief Admin. and Legal Officer
- Issuer ticker
- CLDI
- Reported as of
- 17 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2024, 20:56:02 UTC
- Prior SEC filing
- 25 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Jackson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Wendy Pizarro Campbell filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 20 Jun 2024.
Change
- Previous filing in this sequence was filed on 25 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDI
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- Shares
- +40,000
- Change %
- Price
- Shares after
- 40,000
- Date
- 17 Jun 2024
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 40,000
- Exercise price
- $0.1950
- Footnotes
- F1
CLDI
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- Shares
- +60,000
- Change %
- Price
- Shares after
- 60,000
- Date
- 17 Jun 2024
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 60,000
- Exercise price
- $0.1950
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
Footnote F2
Pursuant to the Issuer's 2023 Plan, on the Grant Date, the Reporting Person was granted 60,000 Options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 5/13/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
SEC remarks
Exhibit 24 - Power of Attorney